On the stock market since 2022, it operates in the world of health and science. It has 2 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 21% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.6M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 47% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 45% a year on average.
The stock sits at $0.27. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 6.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, BIOE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BIOE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.